ProQR Therapeutics N.V. (PRQR) - Market Value

ProQR Therapeutics N.V. (PRQR), a biotechnology business operating in the US and the Netherlands, develops RNA-based therapies to combat hereditary pathologies. This price trend chart illustrates an asset with a market capitalization of 0.18. Financial stability is supported by payments from strategic partners and sufficient liquidity. Development efficiency is being enhanced through the implementation of AI and automated molecule screening systems.

PRQR ProQR Therapeutics: Market Value in the range 07/04/2022 - 11/12/2026

proqr.com - analytical breakdowns and key metrics (PRQR)

- market price and analyst price targets:

Price Chart ProQR Therapeutics|PRQR - Fair Value Consensus

- market capitalization indicators:

Market Value PRQR|PRQR - Full Takeover Company Value

- book value of equity indicators:

Net Assets per Single Share ProQR Therapeutics N.V.|PRQR - Accounting Value of Company|Market Capitalization to Book Value Ratio proqr.com|PRQR - Total Business Assets

- debt and liquidity details:

- business earnings and investment ratios data:

PRQR - Company Net Income|Expected Profit ProQR Therapeutics N.V.|PRQR - Market Cap to Net Income Ratio|Future Price to Earnings ProQR Therapeutics|PRQR - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio PRQR|PRQR - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months ProQR Therapeutics N.V.|PRQR - Earnings per share for the last four quarters|Quarterly EPS earnings growth proqr.com|PRQR - Earnings per share increase in current year|Earnings growth forecast for next year ProQR Therapeutics N.V.

Fundamental company analysis:PRQR (ProQR Therapeutics NV)

The assessment of the margin of safety for ProQR Therapeutics N.V. (PRQR) is based on an analysis of the aggregate value of all shares. This indicator measures market confidence in the assets, reflecting the business's ability to maintain its capitalization during market shocks. By studying the company's market valuation history, an investor can identify critical support levels for the quotes. However, for a biotech firm, the volatility of this metric depends directly on the outcomes of RNA therapy clinical trials. Failures in rare disease research could lead to a sharp devaluation of the issuer.

Direct competitors